Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 Life Science Investing
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting Life Science Investing
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation Life Science Investing
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting Life Science Investing
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology Annual Meeting Life Science Investing
Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides Life Science Investing
Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum Life Science Investing
BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
